Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Exagen (Nasdaq: XGN) will release fourth quarter and full year 2025 financial results before market open on March 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Exagen (Nasdaq: XGN) will release fourth quarter and full year 2025 financial results before market open on March 10, 2026. Management will host a live conference call and webcast to review results.
Details: the call with CEO John Aballi and CFO Jeff Black is at 8:30 a.m. ET / 5:30 a.m. PT; a live webcast and a recorded replay will be available via the company investor relations website.
Details
News Market Reaction – XGN
On Feb 24, the day this news came out, XGN closed 0.27% below the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Earnings release date
- March 10, 2026
- Q4 and full year 2025 financial results release before market open
- Quarter end date
- December 31, 2025
- Fiscal quarter and full year covered by upcoming results
- Conference call time
- 8:30 a.m. ET
- Start time for earnings call hosted by CEO and CFO
- U.S. dial-in
- 877-407-0890
- Domestic participant number for the earnings conference call
- International dial-in
- +1 201-389-0918
- International participant number for the earnings conference call
- Replay end date
- March 24, 2026
- Telephone replay availability end date for the earnings call
- Replay passcode
- 13757484
- Required code to access the telephone replay
- Webcast delay
- 1 hour
- Approximate delay before webcast recording is posted after call
Historical Context
-
Management participation in two New York investor conferences for updates and meetings.
-
Strong Q3 2025 revenue growth, higher gross margin, and improved adjusted EBITDA loss.
-
Acceptance of six ACR 2025 abstracts showcasing biomarkers and diagnostic research.
-
Announcement of Q3 2025 earnings release date and conference call logistics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).
Conference Call & Webcast:
- U.S. dial-in: 877-407-0890
- International dial-in: +1 201-389-0918
- Webcast: Available via the Exagen investor relations website at investors.exagen.com
Replay: A telephone replay will be available until Tuesday, March 24, 2026:
- U.S. replay: 877-660-6853
- International replay: +1 201-612-7415
- Replay passcode: 13757484
- Webcast: A recording of the webcast will be available one hour after the call concludes via the Exagen investor relations website at investors.exagen.com
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow Exagen on LinkedIn.
Contact:
Tina Jacobsen
Exagen Inc.
ir@exagen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.